D. Page

发表

The Human Tumor Atlas Network’s beginning steps toward the future of collaborative multi-omic discovery

D. Page, 2022, Cell reports. Medicine.

corrigenda to Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies [Ann Oncol 26 (2015) 2375-2391, doi: 10.1093/annonc/mdv383]

J. Wolchok, M. Lacouture, M. Postow, 2016 .

Immunotherapy Toxicities.

W. Urba, D. Page, Katherine Sanchez, 2019, Surgical oncology clinics of North America.

Manual scalp cooling in early-stage breast cancer case report: value of caretaker training and patient experience to optimize efficacy and patient selection

W. Urba, A. Conlin, Manaz Rezayee, 2021 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016, Journal for ImmunoTherapy of Cancer.

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.

J. Wolchok, M. Lacouture, M. Postow, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Pretreatment Serum VEGF Is Associated with Clinical Response and Overall Survival in Advanced Melanoma Patients Treated with Ipilimumab

J. Wolchok, F. Hodi, Jun Zhou, 2014, Cancer Immunology Research.

Assessing fracture risk in early stage breast cancer patients treated with aromatase-inhibitors: An enhanced screening approach incorporating trabecular bone score

C. Hudis, D. Hans, S. Patil, 2016, Journal of bone oncology.

Combination Immunotherapy Strategies in Breast Cancer

H. McArthur, D. Page, Brie Chun, 2019, Current Breast Cancer Reports.

Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1

J. Wolchok, P. Paik, S. D'Angelo, 2016, Cancer Immunology Research.

Targeting cytotoxic T-lymphocyte antigen 4 in immunotherapies for melanoma and other cancers.

J. Wolchok, Jianda Yuan, D. Page, 2010, Immunotherapy.

Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer

D. Cescon, B. Vincent, S. Adams, 2019, npj Breast Cancer.

Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy.

J. Wolchok, J. Allison, C. Ariyan, 2010, Cancer immunity.

Immune Checkpoint Blockade

J. Wolchok, J. Naidoo, D. Page, 2019, Methods in Molecular Biology.

Title: A pilot study of preoperative single-dose ipilimumab and/or cryoablation in women with early- stage breast cancer with comprehensive immune profiling. Authors and affiliations:

Janice S. Sung, C. Hudis, L. Norton, 2016 .

Patterns of long-term survival following Ipilimumab (Ipi): the Memorial Sloan Kettering Cancer Center 10-year metastatic melanoma (MM) experience

J. Wolchok, M. Postow, K. Panageas, 2014, Journal of Immunotherapy for Cancer.

Eribulin mesylate in patients with locally advanced unresectable or metastatic breast cancer: results and implications of the clinical trials

B. Ramnaraign, M. Fornier, D. Page, 2015 .

Glimpse into the future: harnessing autophagy to promote anti-tumor immunity with the DRibbles vaccine

B. Fox, W. Urba, Hong-Ming Hu, 2016, Journal of Immunotherapy for Cancer.

Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/− trastuzumab in patients with breast cancer brain metastases

L. Norton, H. McArthur, K. Beal, 2022, NPJ breast cancer.

Pre-operative immunotherapy with tumor cryoablation (cryo) plus ipilimumab (ipi) induces potentially favorable systemic and intratumoral immune effects in early stage breast cancer (ESBC) patients

C. Hudis, L. Norton, J. Wolchok, 2015, Journal of Immunotherapy for Cancer.

Efficacy and toxicity of therapy immediately after treatment with nivolumab in relapsed multiple myeloma

A. Lesokhin, S. Ansell, S. Funt, 2018, Leukemia & lymphoma.

Abstract P2-15-01: Integrated immunologic assessment of tumor infiltrating lymphocytes (TILs) and peripheral blood to assess synergy of cryoablation (cryo) plus ipilimumab (ipi) in early stage breast cancer (ESBC) patients (pts)

Janice S. Sung, R. Emerson, C. Hudis, 2015 .

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.

J. Wolchok, M. Lacouture, M. Postow, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer

D. Cescon, B. Vincent, S. Adams, 2019, npj Breast Cancer.

Current Landscape of Immunotherapy in Breast Cancer: A Review.

G. Hortobagyi, B. Vincent, S. Adams, 2019, JAMA oncology.

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer

H. Rugo, S. Adams, A. Cimino-Mathews, 2021, Journal for ImmunoTherapy of Cancer.

Multiplex immunofluorescence to measure dynamic changes in tumor-infiltrating lymphocytes and PD-L1 in early-stage breast cancer

Brady Bernard, W. Urba, M. Martel, 2021, Breast cancer research : BCR.

Abstract P2-09-03: Updated efficacy of first or second-line pembrolizumab (pembro) plus capecitabine (cape) in metastatic triple negative breast cancer (mTNBC) and correlations with baseline lymphocyte and naïve CD4+ T-cell count

H. McArthur, W. Urba, M. Martel, 2019, Poster Session Abstracts.

Emerging immunotherapy strategies in breast cancer.

H. McArthur, J. Naidoo, D. Page, 2014, Immunotherapy.

Immune modulation for cancer therapy

J. Wolchok, J. Naidoo, D. Page, 2014, British Journal of Cancer.

Tumor mutational burden is a determinant of immune-mediated survival in breast cancer

Guangxu Jin, Michael L. Gatza, Charles M Perou, 2018, Oncoimmunology.

If we build it they will come: targeting the immune response to breast cancer

D. Cescon, S. Adams, H. McArthur, 2019, npj Breast Cancer.

Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.

H. McArthur, D. Page, 2016, Clinical advances in hematology & oncology : H&O.

Novel technologies and emerging biomarkers for personalized cancer immunotherapy

Yingdong Zhao, Holden T Maecker, Ena Wang, 2016, Journal of Immunotherapy for Cancer.

If we build it they will come: targeting the immune response to breast cancer

D. Cescon, S. Adams, H. McArthur, 2019, npj Breast Cancer.

A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling

Janice S. Sung, C. Hudis, L. Norton, 2016, Clinical Cancer Research.

What does the future hold for immunotherapy in cancer?

J. Naidoo, Bob T. Li, D. Page, 2016, Annals of translational medicine.

CTLA-4 antibodies: new directions, new combinations.

J. Wolchok, M. Postow, S. Funt, 2014, Oncology.

Immune modulation in cancer with antibodies.

J. Wolchok, J. Allison, M. Callahan, 2014, Annual review of medicine.

Checkpoint Modulation in Melanoma: An Update on Ipilimumab and Future Directions

J. Wolchok, M. Callahan, M. Postow, 2013, Current Oncology Reports.

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting

J. Wolchok, J. Allison, G. Schwartz, 2010, Cancer.

A Case Series of Metastatic Metaplastic Breast Carcinoma Treated With Anti-PD-1 Therapy

H. McArthur, Brady Bernard, M. Martel, 2021, Frontiers in Oncology.

A Phase Ib Study of Preoperative, Locoregional IRX-2 Cytokine Immunotherapy to Prime Immune Responses in Patients with Early-Stage Breast Cancer

W. Urba, A. Conlin, William L. Redmond, 2019, Clinical Cancer Research.

Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy

Janice S. Sung, R. Emerson, O. Elemento, 2016, Cancer Immunology Research.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Monosomy 17 in potentially curable HER2-amplified breast cancer: prognostic and predictive impact

C. Hudis, L. Norton, E. Brogi, 2017, Breast Cancer Research and Treatment.

Immunotherapy in Triple-Negative Breast Cancer: Present and Future

H. McArthur, Isaac Kim, D. Page, 2019, Current Breast Cancer Reports.

Immunotherapy in breast cancer: An overview of modern checkpoint blockade strategies and vaccines.

H. McArthur, D. Page, Katherine Sanchez, 2016, Current problems in cancer.

T-cell receptor (TCR) DNA deep sequencing to evaluate clonality of tumor-infiltrating lymphocytes (TILs) in early-stage breast cancer patients (pts) receiving preoperative cryoablation (cryo) and/or ipilimumab (ipi).

R. Emerson, C. Hudis, L. Norton, 2014 .

CTLA-4 blockade increases antigen-specific CD8+ T cells in prevaccinated patients with melanoma: three cases

J. Wolchok, S. Adams, J. Allison, 2011, Cancer Immunology, Immunotherapy.

Tumor immunology and cancer immunotherapy: summary of the 2014 SITC primer

P. Sharma, A. Shoushtari, M. Callahan, 2015, Journal of Immunotherapy for Cancer.

The 2014 San Antonio Breast Cancer Symposium: A successful lift-off for breast immunotherapy?

H. McArthur, J. Naidoo, D. Page, 2015, npj Breast Cancer.

Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer

H. McArthur, Brady Bernard, W. Urba, 2022, Journal for ImmunoTherapy of Cancer.

Phase 1b/2 study of intratumoral Ad-RTS-hIL-12 + veledimex in patients with chemotherapy-responsive locally advanced or metastatic breast cancer.

C. Hudis, L. Norton, S. Solomon, 2016 .

Neoadjuvant HER2-targeted therapy +/- immunotherapy with pembrolizumab (neoHIP): An open-label randomized phase II trial.

A. Giuliano, A. Bardia, H. McArthur, 2022, Journal of Clinical Oncology.

Matched T cell repertoire analysis of peripheral blood and tumor-infiltrating lymphocytes (TILs) in early stage breast cancer (ESBC) patients (pts) treated with pre-operative cryoablation (cryo) and/or Ipilimumab (Ipi)

R. Emerson, C. Hudis, L. Norton, 2014, Journal of Immunotherapy for Cancer.

Abstract CT243: Phase 1 study of TAK-676 + pembrolizumab following radiation therapy in patients with advanced non-small-cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), or squamous-cell carcinoma of the head and neck (SCCHN)

R. Gregory, S. Shiao, J. Gibbs, 2022, Cancer Research.

Preoperative checkpoint inhibition (CPI) and cryoablation (Cryo) in women with early-stage breast cancer (ESBC).

G. Plitas, L. Norton, E. Brogi, 2019, Journal of Clinical Oncology.

Multiplex immunofluorescence to measure dynamic changes in tumor-infiltrating lymphocytes and PD-L1 in early-stage breast cancer

Brady Bernard, W. Urba, M. Martel, 2021, Breast Cancer Research.

Pembrolizumab (pembro) with paclitaxel (taxol) or capecitabine (cape) as early treatment of metastatic triple-negative breast cancer (mTNBC).

H. McArthur, W. Urba, M. Martel, 2019, Journal of Clinical Oncology.

A randomized phase II study of peri-operative ipilimumab, nivolumab and cryoablation versus standard care in women with residual, early stage/resectable, triple negative breast cancer after standard-of-care neoadjuvant chemotherapy

L. Norton, S. Solomon, H. McArthur, 2019, Annals of Oncology.

Tumor immunology and cancer immunotherapy: summary of the 2014 SITC primer

P. Sharma, A. Shoushtari, M. Callahan, 2015, Journal of Immunotherapy for Cancer.

The Long PD-1 Receptor Binding Kinetics of Nivolumab May Increase Efficacy of Subsequent Therapy in Relapsed and Refractory Multiple Myeloma Patients

A. Lesokhin, S. Funt, I. Borrello, 2015 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

Immunotherapy in breast cancer: An overview of modern checkpoint blockade strategies and vaccines.

H. McArthur, D. Page, Katherine Sanchez, 2016, Current problems in cancer.

Immune checkpoint blockade.

J. Wolchok, J. Naidoo, D. Page, 2014, Hematology/oncology clinics of North America.